A Randomized, Multi-centric, Double-blind, Placebo-controlled study to Evaluate the Efficacy and Safety of Bromhexine, a serine protease (TMPRSS2) blocker, to prevent COVID-19

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 1,050 人开始时间: 待定最近更新: 2021年7月12日

试验速览

暂无简介。

•Exposure and close contact (defined as being within 6 feet for a period of 15 minutes or more in a 24 hour period or 5 minutes or more for healthcare associated exposure) to a COVID-19 case within 4 days before entering the study
•must agree not to enroll in another investigational study prior to completion of Day 14 of study
•Individuals who have the ability to understand and desire to sign the informed consent
•Age of 18 years or more

•Current Hospitalization
•Receipt of any experimental treatment for 2019-nCoV (off-label, compassionate use, or trial related) within the 30 days prior to the time of the screening evaluation
•Hypersensitivity to bromhexine or any component of the formulation
•Low risk in individuals in close contact (wearing face mask and eye shield)
•Individuals with exposure of less than 15 minutes
•Receipt of any medication for prophylaxis and treatment of 2019-nCoV
•Patients with any related sign and symptoms of COVID-19

发起方